content top

Assessing Foveal Development in Premature and Full-term Infants

Polly A Quiram, MD, PhD (Royal Oak, MI), Kimberly A Drenser, MD (Royal Oak, CA), Meng- Chao Chou, MD (Taipei City, Taiwan, China), Antonio Capone, MD (Royal Oak, MI), Michael T. Trese, MD (Royal Oak, MI) PURPOSE: Postnatal development of the fovea and foveal avascular zone (FAZ) is poorly understood in full term and premature infants. Normal foveal development requires key structural alterations such as formation of the perifoveal capillary...

Read More

Intravitreal Bevacizumab (Avastin) as Salvage Treatment of Refractory Choroidal Neovascularization and Macular Edema from Retinal Vascular Disease

Michael M. Lai, MD, PhD (Royal Oak, MI), Tamer F. Eliwa, MD (Royal Oak, MI), Antonio Capone, MD (Royal Oak, MI), Tarek S. Hassan, MD (Royal Oak, MI), Kimberly A. Drenser, MD (Royal Oak, MI) PURPOSE: To evaluate the anatomic and visual outcomes of intravitreal bevacizumab in patients with neovascular age-related macular degeneration (AMD), diabetic macular edema, and macular edema secondary to retinal vein occlusion unresponsive to...

Read More

Anti-VEGF Therapy for Pediatric Retinopathies: Which Case Is the Right Case?

http://www.evrs.eu/medias/2006/congress/Anti-VEGF-Therapy-for-Pediatric-Retinopathies:-Which-Case-Is-the-Right-Case.swf Kimberly A. Drenser, MD (Royal Oak, CA), Michael T. Trese, MD (Royal Oak, MI), Antonio Capone, MD (Royal Oak, MI) PURPOSE: To review the usefulness and the appropriate case selection of anti-VEGF agents for the treatment of vitreoretinopathies in the pediatric population. METHODS: Patients with either retinopathy of...

Read More
content top